Impediments in Energy Efficient Building Retrofitting: With Special Reference to Public University Buildings in Sri Lanka

In a world where sustainability and energy conservation have taken center stage, the building sector, which happens to be the largest consumer of energy, finds itself at a critical crossroads. As sustainability and energy reduction become increasingly important, building retrofitting is recognized as a viable and sustainable solution. Retrofitting involves integrating new features and technology into existing buildings to enhance their efficiency. Despite the acknowledged need for building retrofitting, there is relatively low concern within the public sector, including university buildings. Various barriers hinder the adoption, implementation, and operation of energy-efficient retrofits in public university buildings in Sri Lanka. This study aimed to investigate these impediments. Qualitative methods were employed, and five professionals, including three architects and two institutional hierarchical heads in Finance and Legal Units, were interviewed. Data analysis was conducted using content analysis. The findings highlighted financial, procurement, energy assessment, technical, and legal aspects as barriers to energy-efficient retrofitting in public university buildings. Among these, technical barriers emerged as the predominant impeding category. Therefore, the authors recommend future studies to focus on in-depth examinations of technical barriers and their impacts on building retrofitting. Authors suggested several policy level implications as well

Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies.

INTRODUCTION: Diabetic retinopathy (DR) is the leading cause of vision loss in the working age population of the developed world. DR encompasses a complex pathology, and one that is reflected in the variety of currently available treatments, which include laser photocoagulation, glucocorticoids, vitrectomy and agents which neutralize vascular endothelial growth factor (VEGF). Whilst these options demonstrate modest clinical benefits, none is yet to fully attenuate clinical progression or reverse damage to the retina. This has led to an interest in developing novel therapies for the condition, such as mediators of angiopoietin signaling axes, immunosuppressants, nonsteroidal anti-inflammatory drugs (NSAIDs), oxidative stress inhibitors and vitriol viscosity inhibitors. Further, preclinical research suggests that gene therapy treatment for DR could provide significant benefits over existing treatments options. AREAS COVERED: Here we review the pathophysiology of DR and provide an overview of currently available treatments. We then outline recent advances made towards improved patient outcomes and highlight the potential of the gene therapy paradigm to revolutionize DR management. EXPERT OPINION: Whilst significant progress has been made towards our understanding of DR, further research is required to enable the development of a detailed spatiotemporal model of the disease. In addition, we hope that improvements in our knowledge of the condition facilitate therapeutic innovations that continue to address unmet medical need and improve patient outcomes, with a focus on the development of targeted medicines.Cambridge Eye Trust Research Councils UK - Medical Research Council the Wellcome Trus

Clinico-demographic characterization of Cutaneous leishmaniasis in patients reporting to two hospitals in Matara and Hambantota districts, Sri Lanka

Background: Cutaneous leishmaniasis (CL) is an established disease in Sri Lanka.Objectives: This study aimed to characterize clinico-demographic pattern of CL, in patients reported to District General Hospital (DGH) Matara and Base Hospital (BH) Tangalle, which report about 100 new cases monthly.Methods: Clinico-demographic findings of 47 CL confirmed patients (>18 years; Slit skin smears (SSS) and/or PCR positive) from preliminary data of a cross sectional study carried out at DGH Matara and BH Tangalle from August/2018 to January /2019 were analysed. Interviewer administered questionnaire was used to gather the demographic data.Results: Median age was 43 years. Out of the 13 cases from DGH Matara, four reported from Urugamuwa and one each from other areas of the district. Of the 34 cases from BHTangalle, 12 were from Beliaththa. Eight SSS negatives became PCR positive and one PCR negative was SSS positive. Majority of the lesions were single (n=40, 85.1%), non-tender (n=38, 80.8%), non-itchy (n=34, 72.3%) and small (< 2cm, n=36, 76.6%) ulcerated nodules (n=14, 29.8%) in upper limbs (n=25, 53.1%) with parasitic grading of 1+ (n=20, 42.5%). Nine patients reported persistent itching without any evidence of secondary pathology. Clinical evidence of secondary bacterial infection presented in four patients and out of them, two had painful lesions. Thirty two lesions were <4 months duration. In addition to ulcerated nodules and plaques, three out of nine papules were ulcerated within 4 months’ by history. Two patients had a family member with CL.Conclusions: Ulceration of papules is a novel observation. Urugamuwa is a possible emerging focus of CL in Matara where Dickwella is the known hot spot. Beliathta could be a main disease focus in Hambantota. This preliminary study based on a smaller sample size needs to be validated with a bigger sample size

Restriction Fragment Length Polymorphism (RFLP) of the Internal Transcribed Spacer 1 (ITS1) region of cutaneous leishmaniasis causing Leishmania donovani in Sri Lanka

Objectives: To isolate PCR quality DNA from punch biopsy samples of 35 suspected cutaneous leishmaniasis (CL) lesions, carry out Internal Transcribed Spacer 1 (ITS1) PCR, analyse Restriction Fragment Length Polymorphism (RFLP), sequence of ITS1 region of 10 randomly selected patient samples and to determine the genetic variation among the causative parasites.Methods: Punch biopsies (3mm) from CL lesions (n=35) were taken and stored in NET buffer at -20C. DNA was extracted using a commercially available kit. ITS1 PCR was carried out using previously described primers. PCR products were digested with Haelll, run in a 1.7 % ethidium bromide gel and visualized under UV light. Same ITS1 PCR products of 10 randomly selected samples were sequenced commercially. Analysis of sequences was carried out with CLUSTALW2 multiple sequence analyzing software.Results: All 35 CL samples showed the same Leishmania donovani ITS1 RFLP pattern. The BLAST search confirmed that the 10 sequenced Sri Lankan strains belong to L. donovani. Multiple sequences analysis showed that Sri Lankan L. donovani strains are highly homogenous in the ITS1 regions. However, the Sri Lankan strains showed, few indels in the ITS1 region when compared with the L. donovani ITS1 sequences originated from India, Sudan and Ethiopia.Conclusions: Cutaneous leishmaniasis in Sri Lanka is still caused only by L. donovani and ITS1 region of the L. donovani strain of Sri Lankan origin is highly homogenous and conserved

First Measurement of Monoenergetic Muon Neutrino Charged Current Interactions

We report the first measurement of monoenergetic muon neutrino charged current interactions. MiniBooNE has isolated 236 MeV muon neutrino events originating from charged kaon decay at rest ($K^+ \rightarrow \mu^+ \nu_\mu$) at the NuMI beamline absorber. These signal $\nu_\mu$-carbon events are distinguished from primarily pion decay in flight $\nu_\mu$ and $\overline{\nu}_\mu$ backgrounds produced at the target station and decay pipe using their arrival time and reconstructed muon energy. The significance of the signal observation is at the 3.9$\sigma$ level. The muon kinetic energy, neutrino-nucleus energy transfer ($\omega=E_\nu-E_\mu$), and total cross section for these events is extracted. This result is the first known-energy, weak-interaction-only probe of the nucleus to yield a measurement of $\omega$ using neutrinos, a quantity thus far only accessible through electron scattering.Comment: 6 pages, 4 figure

Measurement of the antineutrino neutral-current elastic differential cross section

arXiv:1309.7257v1 [hep-ex